Narcolepsy treatment in Sweden: An observational study.
narcolepsy
neuropharmacology
sleep disorders
treatment
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
02
08
2021
received:
03
05
2021
accepted:
05
09
2021
pubmed:
7
10
2021
medline:
5
1
2022
entrez:
6
10
2021
Statut:
ppublish
Résumé
To describe the pharmacological treatments (2005-2017) and the healthcare utilization (1997-2016) for patients with narcolepsy in Sweden in order to create a framework for future organizational and economic analyses. Patients of all ages with a diagnosis of narcolepsy registered in the National Patient Registry in specialist care in Sweden were included and information on treatments for narcolepsy was retrieved from The Swedish Prescribed Drug Register. We collected 2508 patients with narcolepsy, 43,3% men and 56,7% women and 47,9% were prescribed modafenil, 33,8% metylphenidate and 26,2% amphetamine. In total, 3817 treatments were initiated. Patients treated with amphetamine had a higher mean age. More women than men used modafinil, methylphenidate, amphetamine and antidepressants. The narcolepsy population had more outpatient than inpatient healthcare. Patients treated with sodium oxybate had more outpatient visits than other narcolepsy patients, before and during treatment (p = .00). This study gives valuable information on pharmaceutical treatments and healthcare utilization for patients with narcolepsy and can be used to estimate the healthcare cost in the future. Patients with sodium oxybate treatment had more outpatient visits than other patients before and during treatment which may be due to the need to monitor potentially severe side-effects or may indicate that patients with sodium oxybate treatment have a severe disease. The number of included patients was less than expected; however, this may depend on patients escaping our collection of data, which does not contain information from primary care.
Substances chimiques
Antidepressive Agents
0
Sodium Oxybate
7G33012534
Modafinil
R3UK8X3U3D
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-192Subventions
Organisme : UCB
Informations de copyright
© 2021 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.
Références
Dauvilliers Y, Baumann CR, Carlander B, et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry. 2003;74(12):1667-1673.
Schiappa C, Scarpelli S, D'Atri A, Gorgoni M, De Gennaro L. Narcolepsy and emotional experience: a review of the literature. Behav Brain Funct. 2018;14(1):19.
Silber MH, Krahn LE, Olson EJ. Diagnosing narcolepsy: validity and reliability of new diagnostic criteria. Sleep Med. 2002;3(2):109-113.
Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365-376.
Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology. 2001;57(11):2029-2033.
Hallberg P, Smedje H, Eriksson N, et al. Pandemrix-induced narcolepsy is associated with genes related to immunity and neuronal survival. EBioMedicine. 2019;40:595-604.
Lind A, Salami F, Landtblom AM, et al. Immunocyte single cell analysis of vaccine-induced narcolepsy. Eur J Immunol. 2021;51(1):247-249.
Inocente CO, Lavault S, Lecendreux M, et al. Impact of obesity in children with narcolepsy. CNS Neurosci Ther. 2013;19(7):521-528.
Morales Drissi N, Romu T, Landtblom AM, et al. Unexpected fat distribution in adolescents with narcolepsy. Front Endocrinol (Lausanne). 2018;9:728.
Cohen A, Mandrekar J, St Louis EK, Silber MH, Kotagal S. Comorbidities in a community sample of narcolepsy. Sleep Med. 2018;43:14-18.
Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med. 2013;14(6):488-492.
Jennum P, Ibsen R, Knudsen S, Kjellberg J. Comorbidity and mortality of narcolepsy: a controlled retro- and prospective national study. Sleep. 2013;36(6):835-840.
Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. J Sleep Res. 2021;30:e13387.
Witt ST, Drissi NM, Tapper S, et al. Evidence for cognitive resource imbalance in adolescents with narcolepsy. Brain Imaging Behav. 2018;12(2):411-424.
Drissi NM, Szakacs A, Witt ST, et al. Altered brain microstate dynamics in adolescents with narcolepsy. Front Hum Neurosci. 2016;10:369.
Quaedackers L, van Gilst MM, van Mierlo P, et al. Impaired social functioning in children with narcolepsy. Sleep. 2019;42(2).1-6.
Boström I, Lindberger O, Partinen M, Landtblom AM. Vaccination against swine flu caused narcolepsy in several European countries. Health Risk Analysis. 2020;3:180-185. https://doi.org/10.21668/health.risk/2020.3.22.eng
Olsson T, Feltelius N, Persson I, et al. Läkemedelsbehandling vid narkolepsi - bakgrundsdokumentation. 4. Uppsala, Sweden: Swedish Medical Products Agency; 2013.
Hallbook T, Azakacs A, Bialek F, Feltelius N, Landtblom AM, Malmgren K. Narcolepsy-rare disease that has received increased attention. Pandemrix vaccination caused a higher incidence among children and adolescents. Lakartidningen. 2014;111(41):1770-1773.
Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF; American Academy of Sleep M. Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1712-1727.
Hallbook T. Accessed November 20, 2018. https://www.socialstyrelsen.se/stod-i-arbetet/sallsynta-halsotillstand/narkolepsi/
Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med. 2017;281(1):102-104.
Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology. 2013;80(14):1315-1321.
Sarkanen T, Alakuijala A, Julkunen I, Partinen M. Narcolepsy associated with pandemrix vaccine. Curr Neurol Neurosci Rep. 2018;18(7):43.
Bolin K, Niska PA, Pirhonen L, Wasling P, Landtblom AM. The cost utility of pitolisant as narcolepsy treatment. Acta Neurol Scand. 2020;141(4):301-310.
Bolin K, Berling P, Wasling P, Meinild H, Kjellberg J, Jennum P. The cost-utility of sodium oxybate as narcolepsy treatment. Acta Neurol Scand. 2017;136(6):715-720.
Drakatos P, Lykouras D, D'Ancona G, et al. Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice. Sleep Med. 2017;35:80-84.
Jennum P, Ibsen R, Petersen ER, Knudsen S, Kjellberg J. Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners. Sleep Med. 2012;13(8):1086-1093.
Zeman A, Zaiwalla Z. Prescribing sodium oxybate for narcolepsy. BMJ. 2016;353:i2367.
Läkemedelsbehandling vid narkolepsi-ett kunskapsdokument. Swedish Medical Products Agency; 2013.
https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikdatabasen/ Accessed April 1, 2021
https://www.neuroreg.se/narkolepsi. Årsrapport, info@neuroreg.se, 2017-2018
Goldbart A, Peppard P, Finn L, et al. Narcolepsy and predictors of positive MSLTs in the Wisconsin Sleep Cohort. Sleep. 2014;37(6):1043-1051.